Estonya - Estonca - Ravimiamet

bausch + lomb ireland limited - brinsolamiid - silmatilgad, suspensioon - 10mg 1ml 5ml 3tk

Estonya - Estonca - Ravimiamet

santen oy - timolool+tafluprost - silmatilgad, lahus - 5mg+15mcg 1ml 7ml 1tk; 5mg+15mcg 1ml 3ml 3tk; 5mg+15mcg 1ml 5ml 1tk

Estonya - Estonca - Ravimiamet

santen oy - tafluprost - silmatilgad, lahus üheannuselises konteineris - 0,015mg 1ml 0.3ml 90tk; 0,015mg 1ml 0.3ml 30tk

Estonya - Estonca - Ravimiamet

santen oy - tafluprost - silmatilgad, lahus - 0,015mg 1ml 3ml 3tk; 0,015mg 1ml 3ml 1tk; 0,015mg 1ml 5ml 1tk; 0,015mg 1ml 7ml 1tk

Estonya - Estonca - Ravimiamet

sia elvim - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloogilised vahendid - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloogilised vahendid - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmoloogilised vahendid - lucentis on näidustatud täiskasvanute jaoks:ravi neovascular (märg) vanusega seotud makuladegeneratsiooni (amd)raviks nägemispuudega tõttu choroidal neovascularisation (cnv)ravi nägemispuudega tõttu diabeediga macular turse (dme)ravi nägemispuudega tõttu macular turse teisejärguline võrkkesta veeni oklusioon (branch rvo-või kesk-rvo).

Estonya - Estonca - Ravimiamet

novartis baltics sia - deksametasoon+neomütsiin+polümüksiin b - silmatilgad, suspensioon - 1mg+3500rÜ+6000rÜ 1ml 5ml 1tk